Anticipating Breakthroughs in Renal Cell Carcinoma Research

This chapter provides an overview of expected research findings on renal cell carcinoma to be showcased at ASCO 2025, including updates on pivotal trials like Keynote 564 and Checkmate 214. It emphasizes advancements in neoadjuvant and adjuvant treatment strategies, featuring pembrolizumab and innovative combinations aimed at improving patient outcomes.